INTRODUCTION: Neoadjuvant therapy (NT) is increasingly used for localized pancreatic ductal adenocarcinoma (PDAC). The impact of care fragmentation during NT on the outcomes of patients with PDAC is unknown. METHODS: Adult patients with Stage I-III PDAC who received NT and patients who underwent surgery first followed by adjuvant therapy (AT) between 2004 and 2016 were queried from the National Cancer Database. Short- and long-term outcomes were compared between patients who received fragmented care (FC; care provided at >1 hospital) versus integrated care (IC; care at a single institution). RESULTS: Among 6522 patients who underwent NT before pancreatectomy, 3755 (57.6%) received FC and 2767 (42.4%) received IC. While patients who received FC had a longer time to initiation of treatment (33.2 vs. 29.7 days, p < 0.001), there was no difference in median overall survival (OS) (26.7 vs. 26.5 months, p = 0.6). Among patients who underwent upfront surgery followed by AT (n = 15 291), patients who received FC had a longer time from diagnosis to undergoing surgery but less time from surgery to AT and no difference in OS (24.0 vs. 24.0 months, p = 0.910). CONCLUSION: Although care fragmentation was associated with slightly longer times to initiate and complete treatment among patients with localized PDAC, long-term survival outcomes were similar.
INTRODUCTION: Neoadjuvant therapy (NT) is increasingly used for localized pancreatic ductal adenocarcinoma (PDAC). The impact of care fragmentation during NT on the outcomes of patients with PDAC is unknown. METHODS: Adult patients with Stage I-III PDAC who received NT and patients who underwent surgery first followed by adjuvant therapy (AT) between 2004 and 2016 were queried from the National Cancer Database. Short- and long-term outcomes were compared between patients who received fragmented care (FC; care provided at >1 hospital) versus integrated care (IC; care at a single institution). RESULTS: Among 6522 patients who underwent NT before pancreatectomy, 3755 (57.6%) received FC and 2767 (42.4%) received IC. While patients who received FC had a longer time to initiation of treatment (33.2 vs. 29.7 days, p < 0.001), there was no difference in median overall survival (OS) (26.7 vs. 26.5 months, p = 0.6). Among patients who underwent upfront surgery followed by AT (n = 15 291), patients who received FC had a longer time from diagnosis to undergoing surgery but less time from surgery to AT and no difference in OS (24.0 vs. 24.0 months, p = 0.910). CONCLUSION: Although care fragmentation was associated with slightly longer times to initiate and complete treatment among patients with localized PDAC, long-term survival outcomes were similar.
Authors: Ariella M Altman; Keith Wirth; Schelomo Marmor; Emil Lou; Katherine Chang; Jane Y C Hui; Todd M Tuttle; Eric H Jensen; Jason W Denbo Journal: Ann Surg Oncol Date: 2019-07-16 Impact factor: 5.344
Authors: David J Nyweide; Denise L Anthony; Julie P W Bynum; Robert L Strawderman; William B Weeks; Lawrence P Casalino; Elliott S Fisher Journal: JAMA Intern Med Date: 2013-11-11 Impact factor: 21.873
Authors: Jordan M Cloyd; Victor Heh; Timothy M Pawlik; Aslam Ejaz; Mary Dillhoff; Allan Tsung; Terence Williams; Laith Abushahin; John F P Bridges; Heena Santry Journal: J Clin Med Date: 2020-04-15 Impact factor: 4.241
Authors: Syed A Ahmad; Mai Duong; Davendra P S Sohal; Namita S Gandhi; Muhammad Shaalan Beg; Andrea Wang-Gillam; James L Wade; Elena Gabriela Chiorean; Katherine A Guthrie; Andrew M Lowy; Philip A Philip; Howard S Hochster Journal: Ann Surg Date: 2020-09-01 Impact factor: 13.787
Authors: Lena Schreiber; Ryan Zeh; Christina Monsour; Aslam Ejaz; Allan Tsung; Timothy M Pawlik; Eric Miller; Anne Noonan; Somashekar G Krishna; Heena Santry; Jordan M Cloyd Journal: HPB (Oxford) Date: 2021-10-25 Impact factor: 3.842